Scarica l'app Stockscreener
36.24
0.76%
0.225
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RVMD Giù?
Forum
Previsione
Precedente Chiudi:
$36.02
Aprire:
$36.84
Volume 24 ore:
81,268
Relative Volume:
0.04
Capitalizzazione di mercato:
$6.78B
Reddito:
$29.52M
Utile/perdita netta:
$-567.06M
Rapporto P/E:
-9.903
EPS:
-3.66
Flusso di cassa netto:
$-551.11M
1 W Prestazione:
+3.70%
1M Prestazione:
-4.01%
6M Prestazione:
-10.76%
1 anno Prestazione:
-16.60%
Intervallo 1D:
$36.25
$36.84
Intervallo di 1 settimana:
$34.14
$36.84
Portata 52W:
$29.17
$62.40
Revolution Medicines Inc Stock (RVMD) Company Profile
Nome
Revolution Medicines Inc
Settore
Industria
Telefono
415-766-3638
Indirizzo
700 SAGINAW DR, REDWOOD CITY, CA
Confronta RVMD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
36.30 | 6.74B | 29.52M | -567.06M | -551.11M | -3.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
393.00 | 101.51B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.23 | 59.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.25 | 56.69B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
648.10 | 39.57B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
314.12 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-15 | Iniziato | Goldman | Buy |
| 2024-07-16 | Reiterato | Needham | Buy |
| 2024-07-12 | Iniziato | Barclays | Overweight |
| 2024-07-08 | Iniziato | Jefferies | Buy |
| 2024-04-12 | Reiterato | Needham | Buy |
| 2024-04-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | Iniziato | Piper Sandler | Overweight |
| 2024-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-01-04 | Iniziato | Wedbush | Outperform |
| 2023-11-16 | Iniziato | Raymond James | Outperform |
| 2023-02-28 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-12-14 | Iniziato | Needham | Buy |
| 2022-10-21 | Iniziato | Oppenheimer | Outperform |
| 2022-05-20 | Iniziato | BofA Securities | Neutral |
| 2022-03-01 | Aggiornamento | Stifel | Hold → Buy |
| 2021-09-23 | Iniziato | Stifel | Hold |
| 2021-08-12 | Downgrade | Goldman | Buy → Neutral |
| 2021-05-18 | Iniziato | Goldman | Buy |
| 2020-05-21 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-09 | Iniziato | Cowen | Outperform |
| 2020-03-09 | Iniziato | Guggenheim | Buy |
| 2020-03-09 | Iniziato | JP Morgan | Neutral |
Mostra tutto
Revolution Medicines Inc Borsa (RVMD) Ultime notizie
Oppenheimer Reaffirms Outperform on Revolution Medicines, Cites PDAC and NSCLC Trial Progress - MSN
Barclays Reaffirms Buy Rating on Revolution Medicines with $72 Price Target - AInvest
Revolution Medicines’ SWOT analysis: stock poised for growth amid clinical progress - Investing.com Canada
Is It Too Late to Sell Revolution Medicines Inc. Equity WarrantJuly 2025 EndofMonth & Step-by-Step Trade Execution Guides - mustnews.co.kr
Revolution Medicines Receives FDA Breakthrough Therapy Designation for Elironrasib for Lung Cancer - Yahoo Finance
Analysts Are Bullish on These Healthcare Stocks: FibroGen (FGEN), Revolution Medicines (RVMD) - The Globe and Mail
Revolution Medicines’ Earnings Call: Progress Amid Challenges - TipRanks
Revolution Medicines outlines $1.03B–$1.09B net loss guidance for 2025 amid expanded global RAS portfolio strategy - MSN
A Quick Look at Today's Ratings for Revolution Medicines(RVMD.US), With a Forecast Between $56 to $80 - 富途牛牛
Revolution Medicines (RVMD): A High-Risk, High-Reward Biotech Play in the RAS Oncology Space - AInvest
Contradictions Unveiled: RASolute 302 Study Progress and Efficacy Concerns in Latest Earnings Call - AInvest
Revolution Medicines Forecasts $1.03B-$1.09B Net Loss for 2025 Amid RAS Portfolio Expansion - AInvest
Earnings call transcript: Revolution Medicines Q2 2025 sees stock dip after earnings miss - Investing.com
Revolution Medicines August 2025 slides: advancing RAS inhibitor pipeline with promising data - Investing.com India
Revolution Medicines August 2025 slides: advancing RAS inhibitor pipeline with promising data By Investing.com - Investing.com South Africa
Revolution Medicines Advances RAS-Targeted Therapies, Reports Q2 Earnings - AInvest
Revolution Medicines Advances RAS-Targeted Therapies - TipRanks
Revolution Medicines Q2 2025 Earnings Call Transcript - MarketBeat
Revolution Medicines shares rise 2.13% after-hours after reporting strong Phase 3 trial progress and $2 billion funding agreement. - AInvest
Transcript : Revolution Medicines, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Revolution Medicines Doubles Down On Losses To Fuel New Drugs - Finimize
Earnings Flash: (RVMD) Revolution Medicines Q2 Loss $1.31 Vs. FactSet Est. $1.12 Loss - MarketScreener
Revolution Medicines Reports Wider Q2 Loss, Receives Breakthrough Therapy Designation for Elironrasib - AInvest
Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress - GlobeNewswire
Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025 - The Globe and Mail
Revolution Medicines Secures FDA Breakthrough Status, $2B Funding for Cancer Trials | RVMD Stock News - Stock Titan
Tango (TNGX) Q2 Revenue Drops 52% - The Motley Fool
Revolution Medicines shares rise 2.80% intraday after Tango Therapeutics reported dosing first patient in combination trial with Revolution Medicines RAS(ON) inhibitors. - AInvest
What To Expect From Revolution Medicines Inc (RVMD) Q2 2025 Earnings - Yahoo Finance
Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights - GlobeNewswire
Recovery Setup Building in Revolution Medicines Inc. Experts SayLow Risk Equity Screener With Results Shared - metal.it
What analysts say about Revolution Medicines Inc. stockInvest smarter and grow your wealth faster - Jammu Links News
What drives Revolution Medicines Inc. stock priceDiscover high-growth stocks for your portfolio - Jammu Links News
When is Revolution Medicines Inc. stock expected to show significant growthExplosive returns - Jammu Links News
Is it the right time to buy Revolution Medicines Inc. Equity Warrant stockCapitalize on market trends with confidence - Jammu Links News
How does Revolution Medicines Inc. compare to its industry peersSuperior stock growth - Jammu Links News
What is Revolution Medicines Inc. company’s growth strategyUnmatched market gains - Jammu Links News
Is Revolution Medicines Inc. a growth stock or a value stockRapidly growing investment returns - Jammu Links News
Published on: 2025-08-03 19:52:18 - Jammu Links News
Is Revolution Medicines Inc. Equity Warrant a growth stock or a value stockHigh-yield capital appreciation - Jammu Links News
How strong is Revolution Medicines Inc. company’s balance sheetDiscover high-return stocks for your portfolio - Jammu Links News
How many analysts rate Revolution Medicines Inc. Equity Warrant as a “Buy”Harness the power of proven investment plans - Jammu Links News
How volatile is Revolution Medicines Inc. Equity Warrant stock compared to the marketAccelerated earnings growth - Jammu Links News
What is the risk reward ratio of investing in Revolution Medicines Inc. Equity Warrant stockAchieve consistent profits with expert advice - Jammu Links News
Published on: 2025-08-03 11:06:26 - Jammu Links News
What are the latest earnings results for Revolution Medicines Inc. Equity WarrantMarket-leading growth rates - jammulinksnews.com
Is Revolution Medicines Inc. Equity Warrant stock overvalued or undervaluedTriple-digit return opportunities - Jammu Links News
Is Revolution Medicines Inc. a good long term investmentGet exclusive access to professional stock picks - Jammu Links News
What institutional investors are buying Revolution Medicines Inc. Equity Warrant stockDiscover high-return stocks for your portfolio - Jammu Links News
Is Revolution Medicines Inc. stock overvalued or undervaluedMarket-leading profit generation - Jammu Links News
What is the risk reward ratio of investing in Revolution Medicines Inc. stockInvest like a pro with expert recommendations - Jammu Links News
Revolution Medicines Inc Azioni (RVMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.23%
0.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):